Molecular epidemiological of extended-spectrum β-lactamase producing Escherichia coli isolated in Djibouti

Introduction: While the molecular epidemiology of extended-spectrum-b-lactamase (ESBL)-producing E. coli is well known in Europe due to effective surveillance networks and substantial literature, data for Africa are less available, especially in Djibouti. Methodology: We studied 31 isolates of E...

Full description

Saved in:
Bibliographic Details
Main Authors: Julie Plantamura, Aurore Bousquet, Serge Védy, Sébastien Larréché, Christine Bigaillon, Hervé Delacour, Audrey Mérens
Format: Article
Language:English
Published: The Journal of Infection in Developing Countries 2019-08-01
Series:Journal of Infection in Developing Countries
Subjects:
Online Access:https://jidc.org/index.php/journal/article/view/11283
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850035824712744960
author Julie Plantamura
Aurore Bousquet
Serge Védy
Sébastien Larréché
Christine Bigaillon
Hervé Delacour
Audrey Mérens
author_facet Julie Plantamura
Aurore Bousquet
Serge Védy
Sébastien Larréché
Christine Bigaillon
Hervé Delacour
Audrey Mérens
author_sort Julie Plantamura
collection DOAJ
description Introduction: While the molecular epidemiology of extended-spectrum-b-lactamase (ESBL)-producing E. coli is well known in Europe due to effective surveillance networks and substantial literature, data for Africa are less available, especially in Djibouti. Methodology: We studied 31 isolates of ESBL-producing E. coli from Djibouti and compared these molecular results with data available in Africa. Results: Susceptibility rates were 3.2% for ceftazidim, 48.4% for piperacillin-tazobactam, 90.3% for amikacine and 16.1% for ofloxacin. No isolate showed resistance to carbapenems or colistin. 30 E. coli (96.8%) were positive to blaCTX-M-15, 1 (3.2%) to blaCTX-M-14  and 10 (32.3%) to narrow-broad-spectrum blaTEM. No blaSHV were detected. Fluoroquinolone resistance analysis showed that 30 ofloxacin-resistant E. coli had the mutation Ser-83->Leu on the gyrA gene. 24 E. coli (77.4%) harboured the plasmid-borne aac(6 ')-Ib-cr gene. No E. coli carried the genes qnrA, qnrB and qepA. 10 isolates (32.3%) belonging to the ST131 clone. The plasmid incompatibility group most widely represented in our collection was IncFIA/IB/II. Conclusions: There is no major difference with African epidemiology. In particular, we notice the international diffusion of specific clonal group ST131.
format Article
id doaj-art-a64ae1bc3e08401d9708edd5adca2f39
institution DOAJ
issn 1972-2680
language English
publishDate 2019-08-01
publisher The Journal of Infection in Developing Countries
record_format Article
series Journal of Infection in Developing Countries
spelling doaj-art-a64ae1bc3e08401d9708edd5adca2f392025-08-20T02:57:21ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802019-08-01130810.3855/jidc.11283Molecular epidemiological of extended-spectrum β-lactamase producing Escherichia coli isolated in DjiboutiJulie Plantamura0Aurore Bousquet1Serge Védy2Sébastien Larréché3Christine Bigaillon4Hervé Delacour5Audrey Mérens6Department of laboratory, Begin Teaching Military Hospital, Saint-Mandé, FranceDepartment of laboratory, Begin Teaching Military Hospital, Saint-Mandé, FranceDepartement of laboratory, Legouest Teaching Military Hospital, Metz, FranceDepartment of laboratory, Begin Teaching Military Hospital, Saint-Mandé, FranceDepartment of laboratory, Begin Teaching Military Hospital, Saint-Mandé, FranceDepartment of laboratory, Begin Teaching Military Hospital, Saint-Mandé, FranceDepartment of laboratory, Begin Teaching Military Hospital, Saint-Mandé, France Introduction: While the molecular epidemiology of extended-spectrum-b-lactamase (ESBL)-producing E. coli is well known in Europe due to effective surveillance networks and substantial literature, data for Africa are less available, especially in Djibouti. Methodology: We studied 31 isolates of ESBL-producing E. coli from Djibouti and compared these molecular results with data available in Africa. Results: Susceptibility rates were 3.2% for ceftazidim, 48.4% for piperacillin-tazobactam, 90.3% for amikacine and 16.1% for ofloxacin. No isolate showed resistance to carbapenems or colistin. 30 E. coli (96.8%) were positive to blaCTX-M-15, 1 (3.2%) to blaCTX-M-14  and 10 (32.3%) to narrow-broad-spectrum blaTEM. No blaSHV were detected. Fluoroquinolone resistance analysis showed that 30 ofloxacin-resistant E. coli had the mutation Ser-83->Leu on the gyrA gene. 24 E. coli (77.4%) harboured the plasmid-borne aac(6 ')-Ib-cr gene. No E. coli carried the genes qnrA, qnrB and qepA. 10 isolates (32.3%) belonging to the ST131 clone. The plasmid incompatibility group most widely represented in our collection was IncFIA/IB/II. Conclusions: There is no major difference with African epidemiology. In particular, we notice the international diffusion of specific clonal group ST131. https://jidc.org/index.php/journal/article/view/11283E. coliESBLAfricaDjiboutiST131
spellingShingle Julie Plantamura
Aurore Bousquet
Serge Védy
Sébastien Larréché
Christine Bigaillon
Hervé Delacour
Audrey Mérens
Molecular epidemiological of extended-spectrum β-lactamase producing Escherichia coli isolated in Djibouti
Journal of Infection in Developing Countries
E. coli
ESBL
Africa
Djibouti
ST131
title Molecular epidemiological of extended-spectrum β-lactamase producing Escherichia coli isolated in Djibouti
title_full Molecular epidemiological of extended-spectrum β-lactamase producing Escherichia coli isolated in Djibouti
title_fullStr Molecular epidemiological of extended-spectrum β-lactamase producing Escherichia coli isolated in Djibouti
title_full_unstemmed Molecular epidemiological of extended-spectrum β-lactamase producing Escherichia coli isolated in Djibouti
title_short Molecular epidemiological of extended-spectrum β-lactamase producing Escherichia coli isolated in Djibouti
title_sort molecular epidemiological of extended spectrum β lactamase producing escherichia coli isolated in djibouti
topic E. coli
ESBL
Africa
Djibouti
ST131
url https://jidc.org/index.php/journal/article/view/11283
work_keys_str_mv AT julieplantamura molecularepidemiologicalofextendedspectrumblactamaseproducingescherichiacoliisolatedindjibouti
AT aurorebousquet molecularepidemiologicalofextendedspectrumblactamaseproducingescherichiacoliisolatedindjibouti
AT sergevedy molecularepidemiologicalofextendedspectrumblactamaseproducingescherichiacoliisolatedindjibouti
AT sebastienlarreche molecularepidemiologicalofextendedspectrumblactamaseproducingescherichiacoliisolatedindjibouti
AT christinebigaillon molecularepidemiologicalofextendedspectrumblactamaseproducingescherichiacoliisolatedindjibouti
AT hervedelacour molecularepidemiologicalofextendedspectrumblactamaseproducingescherichiacoliisolatedindjibouti
AT audreymerens molecularepidemiologicalofextendedspectrumblactamaseproducingescherichiacoliisolatedindjibouti